Therapeutic Indications

Amikacin is indicated for:

Bacterial infectious disease

Irrespective of gender only Infants (40 days - 1 year old) , Children (1 year - 12 years old)

Amikacin is an aminoglycoside antibiotic which is active against a broad spectrum of Gram-negative organisms, including Pseudomonas spp, Escherichia coli, indole-positive and indole-negative Proteus spp. Klebsiella-Enterobacter-Serratia spp, Salmonella, Shigella, Minea-Herellae, Citrobacter freundii and Providencia spp.

Many strains of these gram-negative organisms resistant to gentamicin and tobramycin may show sensitivity to amikacin in vitro. The principal Gram-positive organism sensitive to amikacin is Staphylococcus aureus, including methicillin-resistant strains. Amikacin has some activity against other Gram-positive organisms including certain strains of Streptococcus pyogenes, Enterococci and Diplococcus pneumoniae.

Amikin is indicated in the short-term treatment of serious infections due to susceptible strains of Gram-negative bacteria. It may also be indicated for the treatment of known or suspected staphylococcal disease.

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Intravenous - 15-20 mg/kg in 2 divided doses daily

Treatment 2: Intramuscular - 15-20 mg/kg in 2 divided doses daily

Bacterial infectious disease

Irrespective of gender only Newborns (0 - 40 days old)

Amikacin is an aminoglycoside antibiotic which is active against a broad spectrum of Gram-negative organisms, including Pseudomonas spp, Escherichia coli, indole-positive and indole-negative Proteus spp. Klebsiella-Enterobacter-Serratia spp, Salmonella, Shigella, Minea-Herellae, Citrobacter freundii and Providencia spp.

Many strains of these gram-negative organisms resistant to gentamicin and tobramycin may show sensitivity to amikacin in vitro. The principal Gram-positive organism sensitive to amikacin is Staphylococcus aureus, including methicillin-resistant strains. Amikacin has some activity against other Gram-positive organisms including certain strains of Streptococcus pyogenes, Enterococci and Diplococcus pneumoniae.

Amikin is indicated in the short-term treatment of serious infections due to susceptible strains of Gram-negative bacteria. It may also be indicated for the treatment of known or suspected staphylococcal disease.

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Intravenous - 15 mg/kg in 2 divided doses daily

Treatment 2: Intramuscular - 15 mg/kg in 2 divided doses daily

Peritonitis

Irrespective of gender only Minors (0 - 18 years old) Adults (18 years old or older)

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Intraperitoneal - 500 mg once

Bacterial infectious disease

Irrespective of gender only Adolescents (12 years - 18 years old) Adults (18 years old or older)

Amikacin is an aminoglycoside antibiotic which is active against a broad spectrum of Gram-negative organisms, including Pseudomonas spp, Escherichia coli, indole-positive and indole-negative Proteus spp. Klebsiella-Enterobacter-Serratia spp, Salmonella, Shigella, Minea-Herellae, Citrobacter freundii and Providencia spp.

Many strains of these gram-negative organisms resistant to gentamicin and tobramycin may show sensitivity to amikacin in vitro. The principal Gram-positive organism sensitive to amikacin is Staphylococcus aureus, including methicillin-resistant strains. Amikacin has some activity against other Gram-positive organisms including certain strains of Streptococcus pyogenes, Enterococci and Diplococcus pneumoniae.

Amikin is indicated in the short-term treatment of serious infections due to susceptible strains of Gram-negative bacteria. It may also be indicated for the treatment of known or suspected staphylococcal disease.

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Intravenous - 15 mg/kg in 2 divided doses daily

Treatment 2: Intramuscular - 15 mg/kg in 2 divided doses daily

Contraindications

Active ingredient Amikacin is contraindicated in the following cases:

Anaesthetics, muscle-relaxing drugs

No gender/age discrimination

The use of amikacin is not recommended in patients under the influence of anaesthetics or muscle-relaxing drugs (including ether, halothane, d-tubocurarine, succinylcholine decamethonium, atracurium, rocuronium, vecuronium or in patients receiving massive transfusions of citrate-anticoagulated blood) as neuromuscular blockade and consequent respiratory depression may occur. If blockade occurs, calcium salts may reverse this phenomenon.

Pregnancy

No gender/age discrimination

Amikacin should be administered to pregnant women and neonatal infants only when clearly needed and under medical supervision.

There are limited data on use of aminoglycosides in pregnancy. Aminoglycosides can cause foetal harm. Aminoglycosides cross the placenta and there have been reports of total, irreversible, bilateral congenital deafness in children whose mothers received streptomycin during pregnancy. Although adverse effects on the foetus or newborns have not been reported in pregnant women treated with other aminoglycosides, the potential for harm exists. If amikacin is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the foetus.

Neurotoxic, ototoxic or nephrotoxic agents

No gender/age discrimination

Concurrent or serial use with other neurotoxic, ototoxic or nephrotoxic agents, particularly bacitracin, cisplatin, amphotericin B, cyclosporine, tacrolimus, cephaloridine, paromomycin, viomycin, polymyxin B, colistin, vancomycin, or other aminoglycosides should be avoided either systemically or topically because of the potential for additive effects.

Hypersensitivity to aminoglycosides

No gender/age discrimination

Myasthenia gravis

No gender/age discrimination